Placebo Q2W

DRUG4 trials

Sponsors

Eli Lilly and Company, MedImmune LLC, R-Pharm International, LLC

Conditions

AsthmaRheumatoid Arthritis

Phase 2

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

CompletedNCT01402986

MedImmune LLCAsthma

Start: 2011-08-31End: 2014-02-28Updated: 2017-04-04

Phase 3

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

TerminatedNCT01198002

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2010-12-31End: 2014-01-31Updated: 2018-05-08

A Study in Participants With Rheumatoid Arthritis

TerminatedNCT01202773

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2011-01-31End: 2014-01-31Updated: 2018-05-14

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

CompletedNCT02760407

R-Pharm International, LLCRheumatoid Arthritis

Start: 2016-06-06End: 2019-11-05Updated: 2023-09-21

Related Papers

The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial

Arthritis Research & Therapy2025-11-14

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

New England Journal of Medicine2022-08-2468 citations

P131 Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study

Lara D. Veeken2021-04-016 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Effect of tralokinumab on GINA control in severe, uncontrolled asthma

2017-09-011 citations

Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

Clinical Pharmacology & Therapeutics2017-07-3110 citations

Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma

2016-09-011 citations

Effect of tralokinumab on serum periostin and IgE levels in uncontrolled severe asthma

2015-09-014 citations

Effect of anti-IL-13 treatment on airway dimensions in severe asthma: Subgroup analysis

2015-09-011 citations

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

RMD Open2015-08-0119 citations

STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma

Clinical Investigation2015-08-0117 citations

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

2015-07-28258 citations

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.

2015-04-1428 citations

Tralokinumab Reduced Acute Exacerbations in a Phase 2 Study of Severe Asthma

MD Conference Express2014-08-01